A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

The goal of this clinical trial is to assess the feasibility of adding a combination of metformin and turmeric as part of a nutritional intervention regimen to the current standard of care, namely, intermittent Androgen Deprivation Therapy (iADT), for patients with castration sensitive biochemical progressive prostate cancer. The main objectives are: * Assess the feasibility of the study population and enrollment. * Evaluate time to PSA relapse with nutritional intervention on iADT. Participants who are receiving iADT will be dispensed Metformin and turmeric and complete a pill diary. Participants will also have blood and stool samples collected and complete quality of life questionnaires. The long-term goal is to further assess the efficacy and safety of this nutritional regimen and the roles of metabolic syndrome, microenvironment/microbiome, and genomic vs epigenomic profiles in the care of these patients through a clinical trial.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• 18 years of age or older.

• History of prior prostatectomy and/or radiation therapy to the prostate.

• Currently have rising PSA levels ≥ 0.2 ng/ml if they have undergone radical prostatectomy, or a PSA ≥ nadir + 2 if they have received only radiotherapy. Patients who were not offered salvage radiotherapy as an alternative treatment will be considered ineligible (due to a high PSA, other medical concerns).

• Currently have at least 2 consecutively rising serum PSA levels more than 1 week apart

• Currently have a PSA doubling time \< 9 months obtained within 60 days of consent.

• Eugonad with testosterone \> 150 ng/dl at time of consent.

• Prior ADT (including iADT) for up to 24 months in association with definitive treatment is permitted if completed at least 12 months prior to consent.

• Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.

• Willing to take study agents at the dose specified with meals.

• Willing to discontinue current vitamin/mineral supplements and use only those provided by study. Herbal supplements may still be used.

Locations
United States
Arkansas
University of Arkansas for Medical Sciences
RECRUITING
Little Rock
Contact Information
Primary
Madison Trujillo
MTrujillo@uams.edu
5016868274
Backup
Aaron Holley
jaholley@uams.edu
5016868274
Time Frame
Start Date: 2024-04-11
Estimated Completion Date: 2027-10
Participants
Target number of participants: 30
Treatments
Experimental: Metformin + Turmeric
Each subject will begin using metformin and turmeric within 7 days of consent. Subjects will start with metformin 500 mg by mouth (po) two times daily (bid) with meals for 14 days. Metformin titration will then increase to 850 milligram (mg) po bid for 14 days before increasing titration to a desired dosage of 1,000 mg po bid. For those subjects currently taking Metformin, they will continue current dose (if 1,000 mg po bid) or titrate dose as just described until maximum dose is achieved.~After two weeks of metformin titration, each subject will start with 1,500 mg turmeric po daily with meals. Dose can be temporarily reduced to 1,000 mg po daily for those who report GI discomfort. If GI discomfort has resolved within one month of the dose reduction, subjects will resume 1,500 mg po daily. If GI discomfort has not resolved the participant may be insturcted to stop taking the study treatment and be removed from the study.
Related Therapeutic Areas
Sponsors
Leads: University of Arkansas

This content was sourced from clinicaltrials.gov